Evaluating Glycemic Control in Patients of South Asian Origin With Type 2 Diabetes Using a Digital Therapeutic Platform: Analysis of Real-World Data.
behavior change
diabetes self-management
digital therapeutics
lifestyle intervention
mobile phone
type 2 diabetes
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
25 03 2021
25 03 2021
Historique:
received:
21
01
2020
accepted:
22
01
2021
revised:
25
09
2020
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
30
9
2021
Statut:
epublish
Résumé
Digital therapeutics are evidence-based therapeutic interventions driven by high-quality software programs for the treatment, prevention, or management of a medical disorder or disease. Many studies in the western population have shown the effectiveness of mobile app-based digital therapeutics for improving glycemic control in patients with type 2 diabetes (T2D). However, few studies have assessed similar outcomes in the South Asian population. This study aims to investigate the real-world effectiveness of the Wellthy CARE digital therapeutic for improving glycemic control among the South Asian population of Indian origin. We analyzed deidentified data from 102 patients with T2D from India enrolled in a 16-week structured self-management program delivered using the Wellthy CARE mobile app. Patients recorded their meals, weight, physical activity, and blood sugar in the app, and they received lessons on self-care behaviors (healthy eating, being active, monitoring, medication adherence, problem solving, healthy coping, and reducing risks); feedback provided by an artificial intelligence-powered chatbot; and periodic interactions with certified diabetes educators via voice calls and chats. The primary outcome of the program was a change in glycated hemoglobin A At the end of 16 weeks, the average change in HbA The use of the Wellthy CARE digital therapeutic for patients with T2D showed a significant reduction in the levels of HbA
Sections du résumé
BACKGROUND
Digital therapeutics are evidence-based therapeutic interventions driven by high-quality software programs for the treatment, prevention, or management of a medical disorder or disease. Many studies in the western population have shown the effectiveness of mobile app-based digital therapeutics for improving glycemic control in patients with type 2 diabetes (T2D). However, few studies have assessed similar outcomes in the South Asian population.
OBJECTIVE
This study aims to investigate the real-world effectiveness of the Wellthy CARE digital therapeutic for improving glycemic control among the South Asian population of Indian origin.
METHODS
We analyzed deidentified data from 102 patients with T2D from India enrolled in a 16-week structured self-management program delivered using the Wellthy CARE mobile app. Patients recorded their meals, weight, physical activity, and blood sugar in the app, and they received lessons on self-care behaviors (healthy eating, being active, monitoring, medication adherence, problem solving, healthy coping, and reducing risks); feedback provided by an artificial intelligence-powered chatbot; and periodic interactions with certified diabetes educators via voice calls and chats. The primary outcome of the program was a change in glycated hemoglobin A
RESULTS
At the end of 16 weeks, the average change in HbA
CONCLUSIONS
The use of the Wellthy CARE digital therapeutic for patients with T2D showed a significant reduction in the levels of HbA
Identifiants
pubmed: 33764306
pii: v23i3e17908
doi: 10.2196/17908
pmc: PMC8074838
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17908Informations de copyright
©Arjun Krishnakumar, Ritika Verma, Rajeev Chawla, Aravind Sosale, Banshi Saboo, Shilpa Joshi, Maaz Shaikh, Abhishek Shah, Siddhesh Kolwankar, Vinod Mattoo. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 25.03.2021.
Références
Diabetes Care. 2019 Jan;42(Suppl 1):S46-S60
pubmed: 30559231
Diabetes Obes Metab. 2017 Sep;19(9):1295-1305
pubmed: 28417575
JMIR Mhealth Uhealth. 2018 Apr 10;6(4):e92
pubmed: 29636320
J Assoc Physicians India. 2005 Sep;53:759-63
pubmed: 16334618
Acta Diabetol. 2017 Aug;54(8):785-794
pubmed: 28585044
Diabetologia. 2020 Apr;63(4):711-721
pubmed: 31901950
J Med Internet Res. 2015 Apr 10;17(4):e92
pubmed: 25863515
Diabetes Ther. 2020 Mar;11(3):607-619
pubmed: 31983028
Diabetologia. 2020 Mar;63(3):453-461
pubmed: 31754750
Diabetes Care. 2019 Jan;42(Suppl 1):S61-S70
pubmed: 30559232
Lancet. 2008 May 24;371(9626):1769-76
pubmed: 18502301
J Diabetes Complications. 2017 Feb;31(2):494-503
pubmed: 27866701
BMC Med Inform Decis Mak. 2018 Feb 20;18(1):12
pubmed: 29458358
Public Health Nutr. 2013 Sep;16(9):1684-92
pubmed: 22995708
BMJ Open. 2016 Apr 20;6(4):e008986
pubmed: 27098819
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
PLoS One. 2015 Sep 18;10(9):e0136202
pubmed: 26383535
Metabolism. 2015 Feb;64(2):338-47
pubmed: 25467842
Indian J Public Health. 2018 Apr-Jun;62(2):104-110
pubmed: 29923533
Patient Educ Couns. 2016 Jun;99(6):926-43
pubmed: 26658704
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Diabetes Care. 2015 Aug;38(8):1441-8
pubmed: 25906786
Clin Nurs Res. 2015 Apr;24(2):188-210
pubmed: 24789938
J Med Internet Res. 2019 Dec 9;21(12):e15401
pubmed: 31815677
Interact J Med Res. 2017 Aug 22;6(2):e14
pubmed: 28829328
JMIR Diabetes. 2020 Jan 20;5(1):e15189
pubmed: 31958064
Nat Biotechnol. 2016 Mar;34(3):239-46
pubmed: 26963544
J Clin Endocrinol Metab. 2019 Jan 1;104(1):127-136
pubmed: 30252100
Diabetes Metab Syndr Obes. 2014 Feb 12;7:45-53
pubmed: 24550679
Ann Glob Health. 2015 Nov-Dec;81(6):830-8
pubmed: 27108150
Diabetes. 2014 Jan;63(1):53-5
pubmed: 24357697
Ther Adv Endocrinol Metab. 2020 Jun 27;11:2042018820937217
pubmed: 32647562
Ann Med Health Sci Res. 2015 Jan-Feb;5(1):59-64
pubmed: 25745579
Arch Public Health. 2015 Sep 25;73:43
pubmed: 26413295